Share this
Back

References:

  1. Keytruda USPI
  2. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N EnglJ Med 2018;378:1789-1801. DOI: 10.1056/NEJMoa1802357.
  3. Eggermont A, Kicinski M, Blank C, et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325/KEYNOTE-054. Eur J Cancer. 2024;211:1-10. doi:10.1016/j.ejca.2024.114327
  4. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage Ill melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.Lancet Oncol. 2021;22(5):643-654. doi:10.1016/51470-2045(21)00065-6
  5. Eggermont AMM, Blank CU, Mandala M, et al. Supplementary appendix to: Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N EnglJ Med 2018;378:1789-1801. DOI:10.1056/NEJMoa1802357

AE-KEY-00950 | Exp 21 May 2027